Can a Small New Stem Cell Pact Move the Needle for Celgene? – 24/7 Wall St.
24/7 Wall St. |
Can a Small New Stem Cell Pact Move the Needle for Celgene?
24/7 Wall St. Celgene Corp. (NASDAQ: CELG) is one of the world’s top biotech stocks now, and its market cap is nearly $100 billion. The company has made a new investment in a stem cell company in Australia, and 24/7 Wall St. wants to know if this is the sort of … Mix Momentum At Considerable Level- Celgene Corporation (NASDAQ:CELG …StreetWise Report |
|
Stem cell therapy for dogs draws support, detractors
Washington Post Instead of giving him bad news, Jaynes’s veterinarian told him about a newly available procedure involving stem cells. In a single day, the vet said, his office could remove cells from Cookie’s fatty tissues, process them and re-inject them into her … |
TheStreet.com |
Athersys Future Hinges on Stem Cell Stroke Study Results
TheStreet.com The company’s stock price plunged last April when MultiStem, the stem cell therapy, failed to benefit ulcerative colitis patients. The MultiStem stroke study is Athersys’ best and perhaps last chance for redemption. Athersys shares were trading around … Great Timing For Athersys, Other Stem Cell Companies Amidst Improving …MarketWatch |
TheStreet.com |
Athersys Future Hinges on Stem Cell Stroke Study Results
TheStreet.com The company’s stock price plunged last April when MultiStem, the stem cell therapy, failed to benefit ulcerative colitis patients. The MultiStem stroke study is Athersys’ best and perhaps last chance for redemption. Athersys shares were trading around … Great Timing For Athersys, Other Stem Cell Companies Amidst Improving …MarketWatch |